The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy
- PMID: 2647992
- PMCID: PMC1292002
- DOI: 10.1177/014107688908200213
The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy
Abstract
Changes in serum lipoproteins were studied in 14 non-insulin dependent diabetics on long-term metformin therapy, after 6 weeks' placebo, and again 6 weeks after restarting active drug therapy. Withdrawal of metformin resulted in a rise of fasting blood glucose, HbA1, serum total and low density lipoprotein (LDL) cholesterol. Restarting the drug reversed these changes. Multivariate analysis showed that serum total and LDL cholesterol varied with treatment but not with glycaemic control. Metformin can lower serum total and LDL cholesterol in non-insulin dependent diabetics and this effect is maintained long term.
Similar articles
-
The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).Diabete Metab. 1991 May;17(1 Pt 2):197-200. Diabete Metab. 1991. PMID: 1936476 Clinical Trial.
-
The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.Diabet Med. 1988 Oct;5(7):653-8. doi: 10.1111/j.1464-5491.1988.tb01074.x. Diabet Med. 1988. PMID: 2975549 Clinical Trial.
-
Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.Diabet Med. 1990 Mar-Apr;7(3):242-5. doi: 10.1111/j.1464-5491.1990.tb01378.x. Diabet Med. 1990. PMID: 2158410 Clinical Trial.
-
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.Eur J Endocrinol. 2008 Jan;158(1):35-46. doi: 10.1530/EJE-07-0500. Eur J Endocrinol. 2008. PMID: 18166815 Clinical Trial.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.Eur J Clin Pharmacol. 1991;41(3):263-5. doi: 10.1007/BF00315441. Eur J Clin Pharmacol. 1991. PMID: 1748145 Clinical Trial.
-
Cellular and Molecular Mechanisms of Metformin Action.Endocr Rev. 2021 Jan 28;42(1):77-96. doi: 10.1210/endrev/bnaa023. Endocr Rev. 2021. PMID: 32897388 Free PMC article. Review.
-
Management of dyslipidemia in people with type 2 diabetes mellitus.Rev Endocr Metab Disord. 2010 Mar;11(1):41-51. doi: 10.1007/s11154-010-9132-6. Rev Endocr Metab Disord. 2010. PMID: 20221703 Review.
-
A risk-benefit assessment of metformin in type 2 diabetes mellitus.Drug Saf. 1999 Jun;20(6):489-503. doi: 10.2165/00002018-199920060-00003. Drug Saf. 1999. PMID: 10392666 Review.
-
Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.Drugs. 1995 May;49(5):721-49. doi: 10.2165/00003495-199549050-00007. Drugs. 1995. PMID: 7601013 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous